Vascular density and expression of vascular endothelial growth factor and angiopoietin-1 using immunofluorescence technique in patients with metastatic renal cell carcinoma treated with first-line sunitinib

J Cancer Res Ther. 2023 Jan-Mar;19(2):520-521. doi: 10.4103/jcrt.jcrt_256_22.

Authors

Marija Kraljević¹, Inga Marijanović¹, Maja Barbarić², Teo Buhovac¹

Affiliations

¹ Oncology Clinic, University Clinical Hospital Mostar, 88 000 Mostar, Bosnia and Herzegovina.
² Laboratory of Morphology, Department of Histology and Embryology, School of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina, Balkans, Bosnia and Herzegovina.

PMID: 37006083
DOI: 10.4103/jcrt.jcrt_256_22

No abstract available

Publication types

Letter

MeSH terms

Angiopoietin-1 / therapeutic use
Antineoplastic Agents* / therapeutic use
Carcinoma, Renal Cell* / pathology
Fluorescent Antibody Technique
Humans
Kidney Neoplasms* / pathology
Microvascular Density
Pyrroles / therapeutic use
Sunitinib / therapeutic use
Vascular Endothelial Growth Factor A / metabolism
Vascular Endothelial Growth Factors / therapeutic use

Substances

Sunitinib
Vascular Endothelial Growth Factor A
Angiopoietin-1
Vascular Endothelial Growth Factors
Pyrroles
Antineoplastic Agents